Drug
TAK-951
TAK-951 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 60.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
60.0%
Based on 3 completed trials
Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
167%(5 trials)
Terminated
2(40%)
Phase Distribution
Ph phase_1
4
80%
Ph phase_2
1
20%
Phase Distribution
4
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
4(80.0%)
Phase 2Efficacy & side effects
1(20.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
60.0%
3 of 5 finished
Non-Completion Rate
40.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(3)
Terminated(2)
Detailed Status
Completed3
Terminated2
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
60.0%
Most Advanced
Phase 2
Trials by Phase
Phase 14 (80.0%)
Phase 21 (20.0%)
Trials by Status
completed360%
terminated240%
Recent Activity
0 active trials
Showing 5 of 5
terminatedphase_1
A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS)
NCT06768658
terminatedphase_1
A Study of TAK-951 in Healthy Adults
NCT06610279
completedphase_1
A Study of TAK-951 in Healthy Adults
NCT05567393
completedphase_2
A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery
NCT04557189
completedphase_1
A Study of TAK-951 in Healthy Adults
NCT04486950
Clinical Trials (5)
Showing 5 of 5 trials
NCT06768658Phase 1
A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS)
NCT06610279Phase 1
A Study of TAK-951 in Healthy Adults
NCT05567393Phase 1
A Study of TAK-951 in Healthy Adults
NCT04557189Phase 2
A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery
NCT04486950Phase 1
A Study of TAK-951 in Healthy Adults
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5